Home » Topics » BioWorld Science

BioWorld Science
RSS

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Lilly discloses new serotonergic agents

Sep. 6, 1996

NS-2710 in development for anxiety

Sep. 6, 1996

Melatonergic agents from ADIR

Sep. 6, 1996

MRI contrast agent from Advanced Magnetics cleared for launch

Sep. 6, 1996

Agreement reached on tests for hepatitis C virus

Sep. 6, 1996

Assays for the diagnosis of Alzheimer's disease

Sep. 6, 1996

Retinoid compound from Sparta enters U.S. clinical trials

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
Japan endorses two iPSC drugs for approval under CEA pathway
BioWorld
Japan is backing conditional approvals of Amchepry (raguneprocel, Sumitomo Pharma Co. Ltd./Racthera Co. Ltd.) and Reheart (Cuorips Inc.), positioning them to...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...